Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNotes PayablesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios

Ensysce Biosciences (ENSCW) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Ensysce Biosciences (ENSCW) over the last 6 years, with Q3 2025 value amounting to $3.2 million.

  • Ensysce Biosciences' Liabilities and Shareholders Equity fell 6612.09% to $3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year increase of 2736.75%. This contributed to the annual value of $5.6 million for FY2024, which is 10668.6% up from last year.
  • As of Q3 2025, Ensysce Biosciences' Liabilities and Shareholders Equity stood at $3.2 million, which was down 6612.09% from $5.6 million recorded in Q2 2025.
  • In the past 5 years, Ensysce Biosciences' Liabilities and Shareholders Equity ranged from a high of $16.4 million in Q4 2021 and a low of $2.7 million during Q4 2023
  • Over the past 5 years, Ensysce Biosciences' median Liabilities and Shareholders Equity value was $5.7 million (recorded in 2022), while the average stood at $6.9 million.
  • In the last 5 years, Ensysce Biosciences' Liabilities and Shareholders Equity skyrocketed by 456657.83% in 2021 and then tumbled by 6835.58% in 2023.
  • Over the past 5 years, Ensysce Biosciences' Liabilities and Shareholders Equity (Quarter) stood at $16.4 million in 2021, then crashed by 64.15% to $5.9 million in 2022, then tumbled by 53.98% to $2.7 million in 2023, then skyrocketed by 106.69% to $5.6 million in 2024, then crashed by 43.2% to $3.2 million in 2025.
  • Its last three reported values are $3.2 million in Q3 2025, $5.6 million for Q2 2025, and $4.6 million during Q1 2025.